|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | ALTANA Pharma |
|---|---|
| Information provided by: | ALTANA Pharma |
| ClinicalTrials.gov Identifier: | NCT00163384 |
Purpose
This trial will compare the effectiveness of one dose of ciclesonide against one dose of budesonide in patients with asthma.
The aim of the present trial is to compare the efficacy of ciclesonide versus budesonide on pulmonary function, symptoms and use of rescue medication in patients with asthma. The onset of action and the safety and tolerability of ciclesonide in comparison to budesonide will also be investigated.
| Condition | Intervention | Phase |
|---|---|---|
|
Asthma |
Drug: Ciclesonide |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Comparative Study of Inhaled Ciclesonide 160 Mcg/Day vs Budesonide 400 Mcg/Day in Patients With Asthma |
| Estimated Enrollment: | 240 |
| Study Start Date: | January 2004 |
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
Main Exclusion Criteria:
Contacts and Locations| Korea, Republic of | |
| Altana Pharma/Nycomed | |
| Busan, Korea, Republic of, 602-715 | |
| Altana Pharma/Nycomed | |
| Chungbuk, Korea, Republic of, 361-711 | |
| Altana Pharma/Nycomed | |
| Chungnam, Korea, Republic of, 330-715 | |
| Altana Pharma/Nycomed | |
| Daegu, Korea, Republic of, 700-712 | |
| Altana Pharma/Nycomed | |
| Daegu, Korea, Republic of, 700-721 | |
| Altana Pharma/Nycomed | |
| Daejeon, Korea, Republic of, 301-721 | |
| Altana Pharma/Nycomed | |
| Gangwon-do, Korea, Republic of, 220-701 | |
| Altana Pharma/Nycomed | |
| Gwangju, Korea, Republic of, 501-757 | |
| Altana Pharma/Nycomed | |
| Gyeonggi-do, Korea, Republic of, 420-767 | |
| Altana Pharma/Nycomed | |
| Gyeonggi-do, Korea, Republic of, 442-721 | |
| Altana Pharma/Nycomed | |
| Jeonju, Korea, Republic of, 561-712 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 134-701 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 138-736 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 137-701 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 140-757 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 135-710 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 133-792 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 120-749 | |
| Altana Pharma/Nycomed | |
| Seoul, Korea, Republic of, 158-710 | |
| Principal Investigator: | Sung-Hak Park, Prof. | The Catholic University of Korea, Kangnam St. Mary's Hospital, Seoul, Korea |
More Information
| ClinicalTrials.gov Identifier: | NCT00163384 History of Changes |
| Other Study ID Numbers: | BY9010/M1-136 |
| Study First Received: | September 12, 2005 |
| Last Updated: | July 16, 2008 |
| Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
|
Asthma Ciclesonide Budesonide |
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Budesonide Ciclesonide Bronchodilator Agents |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Inflammatory Agents Anti-Allergic Agents |